# SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer

> **NCT06819319** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 52 (estimated)

## Conditions studied

- TNBC - Triple-Negative Breast Cancer

## Interventions

- **DRUG:** SHR-A2102 ; Adebrelimab injection

## Key facts

- **NCT ID:** NCT06819319
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-23
- **Primary completion:** 2026-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06819319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06819319, "SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06819319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*